268 related articles for article (PubMed ID: 32651157)
21. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
22. RHEGMATOGENOUS RETINAL DETACHMENT AFTER INTRAARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: The 2016 Founders Award Lecture.
Shields CL; Say EAT; Pefkianaki M; Regillo CD; Caywood EH; Jabbour PM; Shields JA
Retina; 2017 Aug; 37(8):1441-1450. PubMed ID: 27787452
[TBL] [Abstract][Full Text] [Related]
23. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
24. Rhegmatogenous retinal detachment in phakic eyes after posterior chamber phakic intraocular lens implantation for severe myopia.
Martínez-Castillo V; Boixadera A; Verdugo A; Elíes D; Coret A; García-Arumí J
Ophthalmology; 2005 Apr; 112(4):580-5. PubMed ID: 15808247
[TBL] [Abstract][Full Text] [Related]
25. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
Kataja M; Hujanen P; Huhtala H; Kaarniranta K; Tuulonen A; Uusitalo-Jarvinen H
Br J Ophthalmol; 2018 Jul; 102(7):959-965. PubMed ID: 29074495
[TBL] [Abstract][Full Text] [Related]
26. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
27. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
28. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.
Meyer CH; Michels S; Rodrigues EB; Hager A; Mennel S; Schmidt JC; Helb HM; Farah ME
Acta Ophthalmol; 2011 Feb; 89(1):70-5. PubMed ID: 21176118
[TBL] [Abstract][Full Text] [Related]
29. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
30. Pars plana vitrectomy, laser retinopexy, and aqueous tamponade for pseudophakic rhegmatogenous retinal detachment.
Martínez-Castillo V; Zapata MA; Boixadera A; Fonollosa A; García-Arumí J
Ophthalmology; 2007 Feb; 114(2):297-302. PubMed ID: 17056117
[TBL] [Abstract][Full Text] [Related]
31. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658
[TBL] [Abstract][Full Text] [Related]
32. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
34. Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes.
Lee IT; Lampen SIR; Wong TP; Major JC; Wykoff CC
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):883-889. PubMed ID: 30635720
[TBL] [Abstract][Full Text] [Related]
35. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
36. Comparison of pars plana vitrectomy for retinal detachment after failed pneumatic retinopexy and primary pars plana vitrectomy.
Demircan A; Alkın Z; Cakir I; Kesim C; Erdogan G
J Fr Ophtalmol; 2019 Feb; 42(2):146-152. PubMed ID: 30594418
[TBL] [Abstract][Full Text] [Related]
37. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Kung FF; Starr MR; Bui YT; Mejia CA; Bakri SJ
Ophthalmol Retina; 2020 Nov; 4(11):1047-1053. PubMed ID: 32439455
[TBL] [Abstract][Full Text] [Related]
39. Primary repair of retinal detachment with 25-gauge pars plana vitrectomy.
Miller DM; Riemann CD; Foster RE; Petersen MR
Retina; 2008; 28(7):931-6. PubMed ID: 18698293
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
